Rapid drop in serum testosterone after bilateral subcapsular orchiectomy

Area of Science:

• Urology
• Oncology
• Endocrinology

Background:

• Metastatic prostatic carcinoma requires effective testosterone suppression.
• Hormonal therapies like luteinizing hormone-releasing hormone (LH-RH) agonists are common treatments.
• The speed and cost-effectiveness of testosterone suppression methods are critical considerations.

Purpose of the Study:

• To evaluate the speed of testosterone level reduction following bilateral subcapsular orchiectomy.
• To compare the cost-effectiveness of orchiectomy versus LH-RH agonists for managing metastatic prostate cancer.

Main Methods:

• Bilateral subcapsular orchiectomy performed in six patients with metastatic prostatic carcinoma.
• Serial serum testosterone level determination up to 24 hours post-procedure.

Main Results:

• Castrate levels of serum testosterone were achieved approximately 2.5 hours after orchiectomy.
• This represents a significantly faster reduction compared to LH-RH agonists (14-21 days).
• The 36-month cost for orchiectomy was $2,042.00, versus $12,780.00 for LH-RH agonists.

Conclusions:

• Bilateral subcapsular orchiectomy provides rapid and cost-effective testosterone suppression for metastatic prostate cancer.
• Urologists should consider orchiectomy as a primary management strategy over LH-RH agonists due to its speed and economic benefits.
• The efficacy of LH-RH agonists may be limited to one year, further supporting orchiectomy's long-term value.